PDCD1 and ovarian cancer: However, the effectiveness of PD-1/PD-L1 blockade in ovarian cancer has seen limited success and is highly variable between patients and histotypes—the cause of this variability is poorly understood, but is perhaps linked to the degree of genomic instability [99].